Company: SXTPW
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-014334
Chunk: 4

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-02-14
Form: S-1
Chunk 4
---
 |

TRADEMARKS Solely for convenience, our trademarks and tradenames referred to in this prospectus, may appear without the ® or ™ symbols, but such references are not intended to indicate in any way that we will not assert, to the fullest extent under applicable law, our rights to these trademarks and tradenames. All other trademarks, service marks and trade names included or incorporated by reference into this prospectus or the accompanying prospectus are the property of their respective owners. GLOSSARY OF SELECTED TERMS The following are definitions of certain terms that are commonly used in the medical industry and in this prospectus: “8-aminoquinoline” refers to the structural class of antimalarials to which Tafenoquine and Primaquine belong. 8-aminoquinolines are characterized by the presence of an 8-amino substitution on their core quinoline ring, which confers their unique properties including an oxidative Mode of Action and activity against the relapsing liver forms of Plasmodium vivax. “Agency of Record” refers to a marketing/advertising agency used by a Company to develop marketing collateral for a commercial pharmaceutical product. “API” means active pharmaceutical ingredient, the active molecule contained in a pharmaceutical product. ii “Arakoda” means ARAKODA ®, the 60P-owned and FDA-approved product to prevent malaria in travelers, which contains as its active pharmaceutical ingredient, Tafenoquine succinate. “Broad Spectrum of Activity” refers to a molecule or drug that is active against a range of different pathogens. “CAR-T” means chimeric antigen receptor therapy. “CLIA” means The Clinical Laboratory Improvements Amendment of 1988. “Dengue” means a mosquito-borne viral disease occurring in tropical and subtropical areas. “Ethics Committee” a stand-alone or institutional committee responsible for ensuring clinical trials are conducted ethically, and from whom permission is required for a clinical trial to proceed. “EUA” means Emergency Use Authorization. “FDA” refers to the U.S. Food and Drug Administration. “G6PD” means glucose-6-phosphate dehydrogenase. “GMP” means Good Manufacturing Practices. “IND” means investigational new drug application. “Kodatef” is the brand name of Arakoda outside the United States. Kodatef has been approved for use in Australia by the Therapeutic Goods Administration. “Legacy Studies” is a reference to the collection of clinical and non-clinical studies